Norbert Moskovits, MD
Advanced Heart Failure and Transplant Cardiology · Brooklyn, NYNPI 1497713879
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $141,180 of the $159,425 with a category attached, or 88.6%. 29 manufacturers reported payments, led by Merck at 39.0% of the total. Reporting peaked in 2019 at $52,415 and has fallen 99.5% since, to $267 in 2025. Among advanced heart failure and transplant cardiology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 371 payments — averaging $429.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$62K
- Novartis$61K
- AstraZeneca$29K
- Cvrx, Inc.$2K
- Abbott$1K
- Pfizer$648
- plus $3K from 23 others
Across 1 payment — averaging $3500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sensible Medical Innovations Ltd$4K
What the payments were for
- Consulting fees$7,7805%
- Speaking & faculty fees$141,18089%
- Travel & lodging$1,2721%
- Food & beverage$8,9446%
- Education$2490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 44 | $62,245 |
| Novartis | 68 | $60,645 |
| AstraZeneca | 46 | $29,120 |
| Cvrx, Inc. | 4 | $2,204 |
| Abbott | 44 | $1,452 |
| Pfizer | 30 | $648 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $596 |
| Johnson & Johnson | 31 | $518 |
| Boehringer Ingelheim | 15 | $384 |
| Amgen | 15 | $272 |
| Sanofi-aventis U.S. LLC | 12 | $266 |
| Abiomed | 1 | $175 |
| Irhythm Technologies, Inc. | 8 | $154 |
| Gilead | 6 | $109 |
| Actelion Pharmaceuticals US, Inc. | 1 | $99 |
| Alnylam Pharmaceuticals Inc. | 3 | $73 |
| Vifor Pharma, Inc. | 3 | $57 |
| Atricure, Inc. | 2 | $55 |
| Boston Scientific | 3 | $54 |
| Impulse Dynamics (USA) Inc. | 1 | $48 |
| Amarin Pharma, Inc. | 2 | $43 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $42 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Bayer | 2 | $29 |
| Lexicon Pharmaceuticals, Inc. | 1 | $25 |
| Cook Medical LLC | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Chiesi USA, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$88,889
- ENTRESTO$59,575
- FARXIGA$28,721
- Barostim Neo System$2,204
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$297
- Impella$175
- HeartMate 3 Left Ventricular Assist Device$142
- HeartMate$127
How this compares
$159,425 in reported general payments places this provider in the 90th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 17 | $382,415 |
| EntrestoSacubitril/Valsartan | 358 | $360,141 |
| EliquisApixaban | 386 | $347,266 |
| XareltoRivaroxaban | 216 | $176,743 |
| FarxigaDapagliflozin Propanediol | 195 | $149,637 |
| InpefaSotagliflozin | 126 | $89,750 |
| MultaqDronedarone Hcl | 46 | $43,545 |
| VerquvoVericiguat | 47 | $37,335 |
| JanuviaSitagliptin Phosphate | 31 | $31,368 |
| JardianceEmpagliflozin | 28 | $27,908 |
| VascepaIcosapent Ethyl | 43 | $20,637 |
| CorlanorIvabradine Hcl | 33 | $20,378 |
| OzempicSemaglutide | 15 | $19,289 |
| TrulicityDulaglutide | 14 | $12,453 |
| BrilintaTicagrelor | 25 | $11,743 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $648 | $729,680403 claims |
| NovartisEntresto | $60,645 | $360,141358 claims |
| Johnson & JohnsonXarelto | $518 | $176,743216 claims |
| AstraZenecaFarxiga, Brilinta, Lokelma | $29,120 | $171,890231 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $25 | $89,750126 claims |
| MerckVerquvo, Januvia | $62,245 | $68,70378 claims |
| Sanofi-aventis U.S. LLCMultaq | $266 | $43,54546 claims |
| Boehringer IngelheimJardiance, Tradjenta | $384 | $34,87641 claims |
| AmgenCorlanor | $272 | $20,37833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
Other advanced heart failure and transplant cardiology in Brooklyn
- Steven SorciBrooklyn$36K
- Laurie LetarteBrooklyn$20K
- Shudhanshu AlishettiBrooklyn$13K
- Johanna ContrerasNew York$534K
- Scott FeitellRochester$422K
- Sean PinneyNew York$305K
- Mathew MaurerNew York$249K
- Gregg LanierHawthorne$239K
- Michelle BloomMineola$166K
- Stephen PanValhalla$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.